Investors remain skeptical of Nurix Therapeutics' future des...
Investors remain skeptical of Nurix Therapeutics' future despite strong performance, with its forecasted growth rate much lower than the industry's 235%. Current P/S ratio hints that expected growth may not justify a higher P/S, needing a turnaround to satisfy investor sentiment.
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock's 53% Jump Looks Justified
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment